関連する実験動画
Updated: Sep 9, 2025
08:00
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
12.9K
コルキシンとクローナル血液形成の縦断的動態:LoDoCo2試験の探索的副研究
Niekbachsh Mohammadnia1, Liying Xue2, Lucas T W Vestjens1
1Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Journal of the American College of Cardiology
|September 2, 2025
まとめ
低用量コルキシンは,特にTET2変異において,クローナル血液形成 (CH) 拡張を減少させる可能性を示し,心血管疾患のリスクを軽減する方法を示唆した. 確認のためにさらなる研究が必要である.
科学分野:
- 血液学
- 心血管医学
- 薬理学について
背景:
- クローナル血液形成 (CH) は,心臓血管疾患のリスクを増加させる年齢に関連する疾患です.
- CHクローンが大きいと 心血管疾患のリスクが高くなります
- 炎症信号はCHクローンの膨張と心血管疾患に関与しているが,抗炎症療法の効果は不明である.
研究 の 目的:
- 慢性冠動脈疾患の患者におけるCHクローンの増殖に対するコルキシンとプラセボの効果を調査する.
- コルキシンが炎症バイオマーカーに及ぼす影響を時間経過におけるCH状態と関連して評価する.
主な方法:
- LoDoCo2試験の探索的サブ研究では,CHドライバー変異と変異性アレル頻度を追跡するために,高カバーシーケンスを使用した.
- コルキシン投与開始後,1年後に,そして研究終了時に測定した (追跡期間中位は25. 0ヶ月).
- 一般化された線形混合モデルでは,クローン動態を分析し,IL-6とhs-CRPを重要な時間点で測定した.
主要な成果:
- プラセボへのランダム化により,CHクローンのサイズが年間14. 9%増加し,コルキシンでは非有意な6. 3%の増加を示した (P相互作用=0. 13).
- コルキシンは,プラセボと比較して,TET2 CH (P相互作用=0. 04) のクローン増幅を著しく減らし,非DNMT3A CH (P相互作用=0. 01) のIL-6増幅を減少させた.
- コルチキンは全体的に統計的に有意ではないが,クローンの拡大が減少する傾向にある.
結論:
- この探索的分析では,低用量コルキシンがTET2CHのクローン膨張の減少と関連していることが示された.
- コルキシンは,CHドライバー変異の増殖優位性を阻害し,その結果,関連する心血管疾患のリスクを軽減する可能性があります.
- これらの発見を検証するために将来的な研究が必要である.
さらに関連する動画
05:32In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
534
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
7.2K
関連する概念動画
01:22Bone Marrow Sampling and Transplants
493
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
493
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
01:21Hematopoiesis
5.6K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.6K
01:01Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
01:19Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K